GT Biopharma Inc (NAS:GTBP)

$ 2.85 -0.07 (-2.4%) Market Cap: 6.14 Mil Enterprise Value: -3.63 Mil PE Ratio: 0 PB Ratio: 0.74 GF Score: 33/100

GT Biopharma Inc Annual Shareholders Meeting Transcript
Jun 28, 2023
GT Biopharma Inc at HC Wainwright Cell Therapy Virtual Conference Transcript
Feb 28, 2023
GT Biopharma Inc at LD Micro Main Event Transcript
Oct 26, 2022
GT Biopharma Inc Extraordinary Shareholders Meeting Transcript
Oct 10, 2022
GT Biopharma Inc at H C Wainwright Global Investment Conference (Virtual) Transcript
Sep 13, 2022
GT Biopharma Inc Annual Shareholders Meeting Transcript
Jun 08, 2022
GT Biopharma Inc at B Riley Oncology Conference (Virtual) Transcript
Jan 27, 2022
GT Biopharma Inc to Discuss Management Update Call Transcript
Nov 30, 2021
Q2 2021 GT Biopharma Inc Earnings Call Transcript
Aug 13, 2021

$300.3 (-7.40%)

Earnings
GT Biopharma Inc at Raymond James Human Health Innovation Conference (Virtual) Transcript
Jun 22, 2021

GT Biopharma Inc at Raymond James Human Health Innovation Conference (Virtual) Transcript

Jun 22, 2021 / 03:20PM GMT

Release Date Price: $463.2 (-6.93%)

Transcript

Tony Cataldo

GT Biopharma, Inc. - Chairman, CEO & President

All right. Hi, it's Tony Cataldo. For those of you out there, I'm the Chairman and CEO of GT Biopharma, Inc. We're a Nasdaq-traded company, and we uplisted on February 15. And most recent events that are relevant is that we had some tremendous progress. We've been pretty lucky at that. But what I always like to do is start these meetings -- there is a forward-looking statement, which is basically we're not supposed to lie to you, okay?

The good thing about biotech is -- what I always say to folks is I think CEOs talk way too much. And I think really, it's not us that you should listen to at a biotech company. The voice of the company has to be the data: clinical trial data, human FDA clinical trial data. And that's what we're going to focus on today. We're going to tell you about what the TriKE is, we're going to get into the clinical trial data. And then we're going to leave the floor open for those of you who have any questions so that we can address what you came here -- and make sure you get out of this what you sought.

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.